sur INTEGRAGEN (EPA:ALINT)
IntegraGen is heading towards receivership to ensure its survival.
On June 15, 2026, IntegraGen, a company specializing in the genomics of cancer and rare genetic diseases, announced the conversion of its safeguard proceedings into receivership. This decision by the Commercial Court of Évry aims to facilitate discussions with several parties interested in its activities. These discussions revealed interest in IntegraGen's expertise, its teams, and its positioning in the clinical genomics market.
The court-ordered restructuring will allow for the exploration of industrial partnerships, acquisitions, or even a takeover, to ensure business continuity and preserve jobs. IntegraGen specifies that its operations are continuing as normal. The company remains in dialogue with stakeholders and will inform the market of any significant developments.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INTEGRAGEN